Drug intelligence / Profile preview

VOLT3

Development stage: Preclinical
Lead developer: Levolta Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

VOLT3 is a preclinical-stage drug candidate developed by Levolta Pharmaceuticals. The program is being developed in two distinct versions: a prescription (Rx) formulation and an over-the-counter (OTC) formulation. While the specific active pharmaceutical ingredient and biological target have not been publicly disclosed, VOLT3 is part of Levolta's "VOLT" pipeline, which focuses on the development of novel formulations of established therapeutic agents. The company's broader portfolio typically targets pain and inflammatory conditions, such as osteoarthritis, suggesting that VOLT3 is likely a formulation of a non-steroidal anti-inflammatory drug (NSAID) or a similar analgesic agent optimized for improved delivery or safety.

Other names: VOLT3 (Rx)VOLT3 (OTC)VOLT3 prescriptionVOLT-3 prescriptionVOLT 3 prescription

Beyond the preview

Go deeper on VOLT3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VOLT3.

Explore the full profile